PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsLenalidomide
Revlimid(lenalidomide)
Lenalidomide, Revlimid (lenalidomide) is a small molecule pharmaceutical. Lenalidomide was first approved as Revlimid on 2005-12-27. It is used to treat b-cell lymphoma marginal zone, follicular lymphoma, mantle-cell lymphoma, multiple myeloma, and myelodysplastic syndromes in the USA. It has been approved in Europe to treat follicular lymphoma, mantle-cell lymphoma, multiple myeloma, and myelodysplastic syndromes. It is known to target protein cereblon.
Download report
Favorite
SARS-CoV-2 Interaction
BMS
Case Study: Multiple Myeloma
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Lenalidomide, Revlimid (discontinued: Lenalidomide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lenalidomide
Tradename
Company
Number
Date
Products
REVLIMIDBristol Myers SquibbN-021880 RX2005-12-27
6 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
lenalidomideANDA2025-01-02
revlimidNew Drug Application2023-03-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
myelodysplastic syndromes—D009190D46
multiple myeloma—D009101C90.0
mantle-cell lymphoma—D020522—
Agency Specific
FDA
EMA
Expiration
Code
LENALIDOMIDE, REVLIMID, BRISTOL MYERS SQUIBB
2026-05-28ODE-241, ODE-245
2024-02-22ODE-131
Patent Expiration
Patent
Expires
Flag
FDA Information
Lenalidomide, Revlimid, Bristol Myers Squibb
87419292028-03-08U-1983
74658002027-04-27DS, DP
78552172024-11-24DS, DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AX: Other immunosuppressants in atc
— L04AX04: Lenalidomide
HCPCS
No data
Clinical
Clinical Trials
1211 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101—C90.01563101151254572
Plasma cell neoplasmsD054219——1533021101249551
LymphomaD008223—C85.912022237427345
B-cell lymphomaD016393——518513111131
Follicular lymphomaD008224—C823644141378
Myelodysplastic syndromesD009190—D462540411073
Myeloid leukemia acuteD015470—C92.0212011341
T-cell lymphomaD016399——1523—2235
T-cell lymphoma peripheralD016411——1318—2229
Hematologic neoplasmsD019337——35—129
Show 9 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C9560844—4130
Large b-cell lymphoma diffuseD016403—C83.3437713—11118
B-cell chronic lymphocytic leukemiaD015451—C91.142613—290
Non-hodgkin lymphomaD008228—C85.945564—584
Lymphoid leukemiaD007945—C9132543—377
SyndromeD013577——22403—766
PreleukemiaD011289——22364—764
Mantle-cell lymphomaD020522——28355—459
RecurrenceD012008——31242——47
B-cell lymphoma marginal zoneD018442—C88.424256—144
Show 23 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Waldenstrom macroglobulinemiaD008258HP_0005508C88.01411———19
Hodgkin diseaseD006689—C811311———19
T-cell lymphoma cutaneousD016410——76———12
Burkitt lymphomaD002051—C83.7116———12
Precursor cell lymphoblastic leukemia-lymphomaD054198——75——111
Plasma cell leukemiaD007952—C90.138——111
Large-cell lymphoma anaplasticD017728—C84.688———11
CarcinomaD002277—C80.065———9
Adult t-cell leukemia-lymphomaD015459—C91.564———9
T-cell leukemiaD015458——64———9
Show 128 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeuroblastomaD009447EFO_0000621—3————3
Colonic neoplasmsD003110—C182————2
Rectal neoplasmsD012004——2————2
DiseaseD004194EFO_0000408R692————2
Promyelocytic leukemia acuteD015473—C92.42————2
Mediastinal neoplasmsD008479—C38.31————1
Urethral neoplasmsD014523EFO_0003846—1————1
Salivary gland neoplasmsD012468EFO_0003826D111————1
Squamous cell carcinoma of head and neckD000077195——1————1
Mouth neoplasmsD009062EFO_0003868C06.91————1
Show 40 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Abnormal karyotypeD059786——————11
HypoxiaD000860HP_0012418R09.02————11
Patient complianceD010349——————11
Systemic lupus erythematosusD008180HP_0002725M32————11
Medication adherenceD055118EFO_0006344—————11
Patient satisfactionD017060——————11
Personal satisfactionD010549——————11
Patient preferenceD057240——————11
Progression-free survivalD000077982——————11
DermatomyositisD003882EFO_0000398M33————11
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLenalidomide
INNlenalidomide
Description
Lenalidomide is a dicarboximide that consists of 1-oxoisoindoline bearing an amino substituent at position 4 and a 2,6-dioxopiperidin-3-yl group at position 2. It inhibits the secretion of TNF-alpha and has a role as an angiogenesis inhibitor, an antineoplastic agent and an immunomodulator. It is a member of isoindoles, a dicarboximide, a member of piperidones and an aromatic amine. Lenalidomide is a thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.
Classification
Small molecule
Drug classthalidomide derivatives; narcotic agonists/antagonists (normorphine type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O
Identifiers
PDB—
CAS-ID191732-72-6
RxCUI—
ChEMBL IDCHEMBL848
ChEBI ID63791
PubChem CID216326
DrugBankDB00480
UNII IDF0P408N6V4 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CRBN
CRBN
Organism
Homo sapiens
Gene name
CRBN
Gene synonyms
NCBI Gene ID
51185
Protein name
protein cereblon
Protein synonyms
protein x 0001
Uniprot ID
Q9UHW4
Mouse ortholog
Crbn (58799)
protein cereblon (Q8C7D2)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Revlimid – Bristol Myers Squibb
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Revlimid – Celgene
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 22,289 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lenalidomide, Revlimid
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
395,925 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use